Skip to main content
. 2022 Oct 25;57(1):117–126. doi: 10.1111/apt.17248

TABLE 3.

Discontinuation within 104 weeks of treatment.

UC, N = 61 (55.5%)
Treatment duration—weeks, Median (IQR) 13 (7–34)
Reason discontinuation, N (%)
No response 36 (59)
Adverse events 11 (18)
Secondary loss of response 9 (14.8)
Request patient 2 (3.3)
Death after euthanasia (non‐IBD related) 1 (1.6)
Long‐term biochemical remission 1 (1.6)
No effect on arthralgia 1 (1.6)